<article xmlns:ns0="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0219276</article-id>
<article-id pub-id-type="publisher-id">PONE-D-19-16663</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Molecular biology</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Artificial gene amplification and extension</subject><subj-group><subject>Polymerase chain reaction</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Artificial gene amplification and extension</subject><subj-group><subject>Polymerase chain reaction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Extraction techniques</subject><subj-group><subject>DNA extraction</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Eukaryota</subject><subj-group><subject>Protozoans</subject><subj-group><subject>Parasitic protozoans</subject><subj-group><subject>Toxoplasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Fungal diseases</subject><subj-group><subject>Pneumocystis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Albumins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Cerebrospinal fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Cerebrospinal fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Cerebrospinal fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Cerebrospinal fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous system</subject><subj-group><subject>Cerebrospinal fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous system</subject><subj-group><subject>Cerebrospinal fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Amniotic fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Amniotic fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Amniotic fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Amniotic fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>White blood cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Inhibition of polymerase chain reaction: Pathogen-specific controls are better than human gene amplification</article-title>
<alt-title alt-title-type="running-head">PCR inhibition</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Roux</surname>
<given-names>Guillaume</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; original draft</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="fn" rid="currentaff001"><sup>&#164;</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Ravel</surname>
<given-names>Christophe</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Varlet-Marie</surname>
<given-names>Emmanuelle</given-names>
</name>
<role content-type="http://credit.casrai.org/">Resources</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Jendrowiak</surname>
<given-names>Rachel</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Bastien</surname>
<given-names>Patrick</given-names>
</name>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" ns0:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5623-5664</contrib-id>
<name name-style="western">
<surname>Sterkers</surname>
<given-names>Yvon</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; original draft</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Univ. Montpellier, and Laboratoire de Microbiologie, Centre Hospitalier Universitaire (CHU) of N&#238;mes, N&#238;mes, France</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Univ. Montpellier, Centre Hospitalier Universitaire (CHU) of Montpellier, Dept. of Parasitology-Mycology, Research Unit MiVEGEC, CNRS, IRD, Montpellier, France</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" ns0:type="simple">
<name name-style="western">
<surname>Marangoni</surname>
<given-names>Antonella</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1" />
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Universita degli Studi di Bologna Scuola di Medicina e Chirurgia, ITALY</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>We acknowledge the financial support of the "RSI Assurance Maladie Professions Lib&#233;rales - Provinces. C.A.M.P.L.P." for buying the LightCycler 480 (Roche&#174;) real-time PCR equipment. Since this funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; this does not alter our adherence to PLOS ONE policies on sharing data and materials.</p>
</fn>
<fn fn-type="current-aff" id="currentaff001">
<label>&#164;</label>
<p>Current address: Centre Hospitalier de Gap, Laboratoire de Biologie, Gap, France</p>
</fn>
<corresp id="cor001">* E-mail: <email ns0:type="simple">yvon.sterkers@umontpellier.fr</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>9</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>14</volume>
<issue>9</issue>
<elocation-id>e0219276</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>6</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>8</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Roux et al</copyright-holder>
<license ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" ns0:href="info:doi/10.1371/journal.pone.0219276" />
<abstract>
<p>PCR inhibition is frequent in medical microbiology routine practice and may lead to false-negative results; however there is no consensus on how to detect it. Pathogen-specific and human gene amplifications are widely used to detect PCR inhibition. We aimed at comparing the value of PCR inhibitor detection using these two methods. We analysed Cp shifts (&#916;Cp) obtained from qPCRs targeting either the albumin gene or the pathogen-specific sequence used in two laboratory-developed microbiological qPCR assays. 3152 samples including various matrixes were included. Pathogen-specific amplification and albumin qPCR identified 62/3152 samples (2.0%), and 409/3152 (13.0%) samples, respectively, as inhibited. Only 16 samples were detected using both methods. In addition, the use of the Youden's index failed to determine adequate Cp thresholds for albumin qPCR, even when we distinguished among the different sample matrixes. qPCR targeting the albumin gene therefore appears not adequate to identify the presence of PCR inhibitors in microbiological PCR assays. Our data may be extrapolated to other heterologous targets and should discourage their use to assess the presence of PCR inhibition in microbiological PCR assays.</p>
</abstract>
<funding-group>
<funding-statement>"RSI Assurance Maladie Professions Lib&#233;rales - Provinces. C.A.M.P.L.P." has paid the LightCycler 480 (Roche&#174;) real-time PCR equipment in 2009. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="4" />
<table-count count="1" />
<page-count count="11" />
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Molecular biology and particularly real-time PCR (qPCR) has revolutionized the biological diagnosis of infectious diseases. Nonetheless, PCR may fail because it is based on an enzymatic reaction susceptible to various mechanisms of inhibition [<xref ref-type="bibr" rid="pone.0219276.ref001">1</xref>]. Inhibition of PCR reaction is frequent in clinical microbiology and exposes to the risk of false negative results, hence PCR inhibition screening is recommended [<xref ref-type="bibr" rid="pone.0219276.ref002">2</xref>, <xref ref-type="bibr" rid="pone.0219276.ref003">3</xref>]. PCR inhibition appears as a hardly predictable event and data about its actual frequency in routine practice of clinical biology laboratories are scarce [<xref ref-type="bibr" rid="pone.0219276.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0219276.ref005">5</xref>]. Differential susceptibility of each type of qPCR to different inhibitors and heterogeneity of sample matrixes make its detection non trivial. Many methods to detect PCR inhibition have been reported and some guidelines have been published. The use of PCR controls with a defined quantity of DNA molecules to check for the presence of a Cp switch due to the presence of inhibitors in the sample extract is relevant; however it is risky since technicians may have to manipulate and distribute target DNA, thus increasing the risk of inter-well contamination. 'Internal' amplification controls, based on alien DNA added at a low concentration in the specimen before DNA extraction, and of which the presence must be checked in a duplex PCR together with the target, is also highly relevant. Most of commercial inhibition controls are based on this principle. The rationale of using a human gene as an extraction or inhibition control is less acceptable because the human DNA target is present in high quantity in the sample as compared to the target DNA [<xref ref-type="bibr" rid="pone.0219276.ref006">6</xref>]. Importantly, there is presently no consensus for PCR inhibition detection in routine practices. For example, in the single field of molecular diagnosis of toxoplasmosis in France, seven different methods are used to detect PCR inhibition in 30 laboratories [<xref ref-type="bibr" rid="pone.0219276.ref007">7</xref>]. Most of them use either a pathogen pathogen-specific PCR or a human gene amplification method. The former is an internal control made of either genomic <italic>T</italic>. <italic>gondii</italic> DNA or a plasmid containing the targeted pathogen DNA sequence. It has one major drawback which is the increased risk of false positive results due to increased amounts of amplicons and airborne contamination of reaction wells. Amplification controls may be prepared from genomic DNA (as in our <italic>Toxoplasma</italic>-PCR assay) or from the target DNA sequence cloned in a plasmid (as in our <italic>Pneumocystis</italic>-PCR assay). One development of the plasmid strategy is to clone a chimeric sequence to be amplified by the same primers than the PCR target but detected by specific probe(s) [<xref ref-type="bibr" rid="pone.0219276.ref008">8</xref>&#8211;<xref ref-type="bibr" rid="pone.0219276.ref011">11</xref>]. In the second type of method, albumin, beta-globin or human RNase P genes are targeted. This method is found attractive since (i) they can be implemented in all qPCR assays involving human samples; and (ii) they constitute a complete process control for DNA extraction and amplification. Yet, human gene qPCR cycle of positivity (Cp) depends also on the initial human DNA content or cellularity in the clinical sample, which is highly variable. Indeed, DNA content or cellularity depends on the size/volume of the sample, the matrix, <italic>i</italic>.<italic>e</italic>. the nature of the sample, such as blood or cerebrospinal fluid, and on the pathophysiological state of the patients. The control of DNA extraction is another critical step of molecular diagnosis, but was not explored in our study. In addition, it is reported in the literature that PCR methods differing by their primers and/or amplified sequence have variable susceptibility to inhibitors [<xref ref-type="bibr" rid="pone.0219276.ref012">12</xref>&#8211;<xref ref-type="bibr" rid="pone.0219276.ref014">14</xref>]. These studies tend to invalidate the assumption that absence of inhibition in a qPCR targeting any human gene has a good predictive value for assessing inhibition in a qPCR targeting a pathogen. Consequently, it is critical to assess the performances of human gene-based PCR inhibition screening methods in clinical samples in clinical microbiology routine practice.</p>
<p>In this study, (i) we analyse the frequency of PCR inhibition in a large range of clinical samples and (ii) we show that human gene-based qPCR methods are not efficient to affirm the presence/absence of PCR inhibitors.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Methods</title>
<p>We retrospectively analysed <italic>Toxoplasma</italic> and <italic>Pneumocystis</italic> qPCR tests for all the clinical samples analysed in 2016 in the Department of Parasitology-Mycology at the academic hospital of Montpellier (Montpellier, France).</p>
<sec id="sec003">
<title>DNA extraction</title>
<p>The DNA extraction method was dependent on the PCR assay and the sample matrix. For <italic>Pneumocystis</italic>-PCR, all types of respiratory samples were analysed, including bronchoalveolar lavage fluid (BALF), sputum, bronchoaspiration, nasal aspiration and pleural fluid; DNA was extracted using QIAamp DNA minikit (Qiagen) according to the manufacturer specifications. For <italic>Toxoplasma</italic>-PCR, the DNA extraction method depended on the matrix. For low cellular samples such as cerebrospinal fluids (CSF), aqueous humor, amniotic fluids and crystal clear BALF, DNA was extracted using the Tween-Nonidet-NaOH method[<xref ref-type="bibr" rid="pone.0219276.ref015">15</xref>]. When <italic>Pneumocystis</italic> and <italic>Toxoplasma</italic> qPCRs were performed on the same sample, QIAamp DNA minikit (Qiagen) was used. Other samples were processed using protein precipitation solution (A795A; Promega, France)[<xref ref-type="bibr" rid="pone.0219276.ref016">16</xref>]. As recommended, DNA extracts were then stored at&#8211; 20&#176;C prior to PCR for best preservation[<xref ref-type="bibr" rid="pone.0219276.ref017">17</xref>].</p>
</sec>
<sec id="sec004">
<title><italic>Toxoplasma</italic> and <italic>Pneumocystis</italic> qPCR assays</title>
<p>The <italic>Toxoplasma</italic> qPCR targeted the &#8216;rep529&#8217; sequence (AF146527) and was performed as described by Reischl et al. [<xref ref-type="bibr" rid="pone.0219276.ref018">18</xref>]. The <italic>Pneumocystis</italic> qPCR targeted the major surface glycoprotein gene (AF372980) and was performed as described by Fillaux et al.[<xref ref-type="bibr" rid="pone.0219276.ref019">19</xref>]. We used LC480&#174; Probe Master 2X (Roche&#174;) for both qPCR and Uracil-N-Glycosylase (Roche&#174;) for <italic>Toxoplasma</italic> qPCR. Each PCR well contained 15 &#956;L of mix and 5 &#956;L of DNA extract for <italic>Toxoplasma</italic> qPCR and 18 &#956;L of mix and 2 &#956;L of DNA extract for <italic>Pneumocystis</italic> qPCR. Amplification and detection occurred in LightCycler&#174; 480 (Roche) and raw fluorescence data were analysed using the LightCycler&#174; 480 software release 1.5.0 (Roche). Cycles of positivity were determined by the second derivative method.</p>
</sec>
<sec id="sec005">
<title>PCR controls and definition of inhibition</title>
<p>Each PCR plate contained one well for negative control (sterile water) and one for positive control (calibrated positive sample). Cp values of positive plate controls were plotted into Levey-Jennings charts and interpreted according to the Westgard rules[<xref ref-type="bibr" rid="pone.0219276.ref020">20</xref>]. DNA extraction control was performed in routine practice by qPCR targeting the human albumin gene[<xref ref-type="bibr" rid="pone.0219276.ref021">21</xref>]. Amplification controls were made of reaction wells containing pathogen DNA on top of the patient DNA extract. For the <italic>Toxoplasma</italic> qPCR assay, this pathogen-specific amplification positive control was prepared from a 10<sup>5</sup> <italic>T</italic>. <italic>gondii</italic> tachyzoites/mL freeze-dried standard as described in Varlet-Marie et al. [<xref ref-type="bibr" rid="pone.0219276.ref022">22</xref>]; 2 &#956;L of <italic>T</italic>. <italic>gondii</italic> DNA extract were added to obtain a final concentration of 1.5 <italic>T</italic>. <italic>gondii</italic> genome/tube for which the expected Cp value is 35.2 &#177;1.5. The control was performed in duplicate. A sample was considered inhibited if both amplification control wells showed a Cp&gt;38. If only one well showed a Cp&gt;38, we considered this as irrelevant and due to stochastic events. For <italic>Pneumocystis</italic>-qPCR, the amplification control was made of the pathogen target DNA sequence, which had been cloned into pGEM-T easy&#174;. Plasmid DNA maxipreparation (Qiagen Maxiprep&#174;) was then diluted in order to reach a Cp of 30.1 &#177;1.2, and 1 &#956;L of this dilution was added to the reaction tube. A <italic>Pneumocystis</italic>-qPCR reaction was considered inhibited if the Cp difference between amplification control and the positive plate control was &#8805;3. In this study, albumin-qPCR was considered as inhibited if the difference between the Cp of albumin-qPCR (Cp<sub>alb</sub>) obtained for a sample and the mean Cp<sub>alb</sub> for the matrix considered was &#8805;3.</p>
</sec>
<sec id="sec006">
<title>Data management</title>
<p>PCR results and bio-clinical data were exported from LightCycler&#174; 480 release 1.5.0 software (Roche&#174;) and DxLab&#174; software (MedaSys&#174;) respectively, to spreadsheets (<xref ref-type="supplementary-material" rid="pone.0219276.s002">S1</xref> and <xref ref-type="supplementary-material" rid="pone.0219276.s003">S2</xref> Figs).</p>
</sec>
<sec id="sec007">
<title>Determination of the PCR efficiencies</title>
<p>PCR efficiencies of the techniques were determined using a standard curve generated by performing a logarithmic serial dilution of DNA extracts. The standard curves demonstrating a linear relationship between the logarithm of the copy number and the Cp value, allows to determine the PCR efficiency using: Efficiency = -1+10exp(-1/slope) [<xref ref-type="bibr" rid="pone.0219276.ref023">23</xref>].</p>
</sec>
<sec id="sec008">
<title>Statistics</title>
<p>Data were analyzed using R 3.4.0 and RStudio 1.0.143 softwares [<xref ref-type="bibr" rid="pone.0219276.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0219276.ref025">25</xref>]. We calculated the Youden&#8217;s index considering the pathogen-specific amplification control as the reference method to detect PCR inhibition. The Youden&#8217;s index combines sensitivity and specificity into a single measure (Sensitivity + Specificity&#8211; 1) and its value ranges between -1 and 1. A value of 1 indicates that there are neither false positive nor false negative results. The best Cp<sub>alb</sub> cut-off values of albumin-qPCR to detect inhibition were defined using the Youden's index. Sensitivities and specificities of these Cp<sub>alb</sub> cut-offs were next compared by binomial tests to the 95% theoretical value in order to assess their inferiority. Correlation of Cp<sub>alb</sub> to leucocyte counts was assessed using Spearman&#8217;s rank correlation. Holm correction was performed for all the tests. Samples without Cp<sub>alb</sub> value due to a flat amplification curve were excluded from the graph and the correlation. A p value &lt;0.05 was considered as significant.</p>
</sec>
<sec id="sec009">
<title>Ethical approval and informed consent</title>
<p>This work was carried out in accordance with the relevant guidelines and regulations; it does not include potentially identifying patient/participant information. The study corresponds to a non-interventional retrospective study and according to the French Health Public Law (CSP Art L1121-1.1), such studies are exempt from informed consent requirement and do not require approval by an ethics committee.</p>
</sec>
</sec>
<sec id="sec010" sec-type="conclusions">
<title>Results and discussion</title>
<sec id="sec011">
<title>General description</title>
<p>The Dept. of Parasitology-Mycology is a regional and national reference centre which coordinates the "Molecular biology pole" of the National Reference Center for Toxoplasmosis (<ext-link ext-link-type="uri" ns0:href="http://cnrtoxoplasmose.chu-reims.fr/" ns0:type="simple">http://cnrtoxoplasmose.chu-reims.fr</ext-link>). The laboratory is accredited according to ISO 15189:2012 for the <italic>Toxoplasma</italic> and <italic>Pneumocystis</italic> PCR assays. The <italic>Toxoplasma</italic>-qPCR assay is being used in routine since July 2009, &gt;17000 clinical samples have been routinely tested, and PCR efficiency is regularly controlled and found at &#8805;97.5% [<xref ref-type="bibr" rid="pone.0219276.ref018">18</xref>]. For the <italic>Pneumocystis-</italic>qPCR assay, the corresponding features are March 2013, &gt;2500, and 90 &#177;9%. PCR efficiency of the albumin qPCR was 98.5% (<xref ref-type="fig" rid="pone.0219276.g001">Fig 1</xref>). These laboratory-developed qPCR assays may therefore be considered as robust and finely optimized.</p>
<fig id="pone.0219276.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0219276.g001</object-id>
<label>Fig 1</label>
<caption>
<title>PCR efficiencies.</title>
<p><bold>A</bold>. LightCycler real-time PCR amplification curves in a serial dilution assay. <bold>B-D</bold>. PCR efficiencies were determined in triplicate in two/three independent experiments. PCRs were performed in triplicate on five/six samples representing a 10-fold serial dilution. All standard curves demonstrated a linear relationship between the logarithm of the copy number and the Cp value, allowing determining the PCR Efficiency using: Efficiency = -1+10exp(-1/slope).</p>
</caption>
<graphic mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0219276.g001" ns0:type="simple" />
</fig>
<p>During the year 2016, 3152 samples were referred to the laboratory as part of the routine activity (<xref ref-type="fig" rid="pone.0219276.g002">Fig 2</xref>): 2225 samples were analysed by <italic>Toxoplasma</italic>-qPCR, 964 by <italic>Pneumocystis</italic>-qPCR, and 37 samples were analysed by both methods (<xref ref-type="supplementary-material" rid="pone.0219276.s001">S1 Table</xref>). Two samples analysed by <italic>Toxoplasma</italic>-qPCR were excluded from this study, one due to cancellation of the analysis and another due to identity problem (<xref ref-type="supplementary-material" rid="pone.0219276.s002">S1</xref> and <xref ref-type="supplementary-material" rid="pone.0219276.s003">S2</xref> Figs). Most <italic>Toxoplasma</italic>-qPCR analysed samples were blood samples (1874 out of 2225), followed by 95 CSF and 114 postnatal samples (<xref ref-type="table" rid="pone.0219276.t001">Table 1</xref>). No <italic>Pneumocystis</italic>-qPCR samples had to be excluded from the analysis; the 964 <italic>Pneumocystis</italic>-qPCR samples comprised 787 BALF and 141 sputa samples (<xref ref-type="table" rid="pone.0219276.t001">Table 1</xref>). The percentage of positive samples for the <italic>Toxoplasma</italic>-qPCR was 1.7%, ranging from 0.3% for the blood to 12% for the amniotic fluid samples. For <italic>Pneumocystis</italic>-qPCR, the percentage of positive sample was 7.1% (<xref ref-type="table" rid="pone.0219276.t001">Table 1</xref>).</p>
<fig id="pone.0219276.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0219276.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Venn diagram of number of analyzed samples.</title>
<p>Inhibited samples: Samples were considered inhibited if the Cp of the pathogen-specific control was &gt;38 for both wells for <italic>Toxoplasma</italic>-PCR (N = 45), and if &#916;Cp &#8805;3 for <italic>Pneumocystis</italic>-PCR (N = 17). Cp(albumin)&gt;threshold: For albumin-PCR, the inhibition threshold was the mean Cp<sub>alb</sub> + 3 for a given matrix (see <xref ref-type="sec" rid="sec002">Methods</xref> and <xref ref-type="table" rid="pone.0219276.t001">Table 1</xref>).</p>
</caption>
<graphic mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0219276.g002" ns0:type="simple" />
</fig>
<table-wrap id="pone.0219276.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0219276.t001</object-id>
<label>Table 1</label> <caption><title>Frequency of PCR inhibition as a function of sample matrix for <italic>Toxoplasma</italic> PCR and <italic>Pneumocystis</italic> PCR.</title></caption>
<alternatives>
<graphic id="pone.0219276.t001g" mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0219276.t001" ns0:type="simple" />
<table>
<colgroup>
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
</colgroup>
<thead>
<tr>
<th align="left" style="background-color:#FFFFFF">&#160;</th>
<th align="left" style="background-color:#FFFFFF">&#160;</th>
<th align="left" style="background-color:#FFFFFF">&#160;</th>
<th align="left" style="background-color:#FFFFFF">&#160;</th>
<th align="center" colspan="5" style="background-color:#FFFFFF"><italic>Toxoplasma</italic> PCR</th>
<th align="center" style="background-color:#FFFFFF"><italic>&#160;</italic></th>
<th align="center" style="background-color:#FFFFFF"><italic>&#160;</italic></th>
<th align="center" colspan="5" style="background-color:#FFFFFF"><italic>Pneumocystis</italic> PCR</th>
</tr>
<tr>
<th align="left" style="background-color:#FFFFFF">&#160;</th>
<th align="left" style="background-color:#FFFFFF">&#160;</th>
<th align="center" colspan="2" style="background-color:#FFFFFF">Positive samples</th>
<th align="center" colspan="2" style="background-color:#FFFFFF">Inhibited samples</th>
<th align="center" colspan="3" style="background-color:#FFFFFF">Cp<sub>alb</sub>&#8805; threshold<xref ref-type="table-fn" rid="t001fn002">*</xref></th>
<th align="center" colspan="2" style="background-color:#FFFFFF">Positive samples</th>
<th align="center" colspan="2" style="background-color:#FFFFFF">Inhibited samples</th>
<th align="center" colspan="3" style="background-color:#FFFFFF">Cp<sub>alb</sub>&#8805; threshold<xref ref-type="table-fn" rid="t001fn002">*</xref></th>
</tr>
<tr>
<th align="left" style="background-color:#FFFFFF">&#160;</th>
<th align="left" style="background-color:#FFFFFF">&#160;</th>
<th align="center" style="background-color:#FFFFFF">Nber</th>
<th align="center" style="background-color:#FFFFFF">%</th>
<th align="center" style="background-color:#FFFFFF">Nber</th>
<th align="center" style="background-color:#FFFFFF">%</th>
<th align="center" style="background-color:#FFFFFF">Threshold</th>
<th align="center" style="background-color:#FFFFFF">Nber</th>
<th align="center" style="background-color:#FFFFFF">%</th>
<th align="center" style="background-color:#FFFFFF">Nber</th>
<th align="center" style="background-color:#FFFFFF">%</th>
<th align="center" style="background-color:#FFFFFF">Nber</th>
<th align="center" style="background-color:#FFFFFF">%</th>
<th align="center" style="background-color:#FFFFFF">Threshold</th>
<th align="center" style="background-color:#FFFFFF">Nber</th>
<th align="center" style="background-color:#FFFFFF">%</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" style="background-color:#FFFFFF">Blood</td>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="center" style="background-color:#FFFFFF">4/1309</td>
<td align="center" style="background-color:#FFFFFF">0.3</td>
<td align="center" style="background-color:#FFFFFF">31/1309</td>
<td align="center" style="background-color:#FFFFFF">2,3</td>
<td align="center" style="background-color:#FFFFFF">23,1</td>
<td align="center" style="background-color:#FFFFFF">104/1309</td>
<td align="center" style="background-color:#FFFFFF">7,9</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" colspan="2" style="background-color:#FFFFFF">Blood from leucopenic patient</td>
<td align="center" style="background-color:#FFFFFF">7/565</td>
<td align="center" style="background-color:#FFFFFF">1.2</td>
<td align="center" style="background-color:#FFFFFF">2/565</td>
<td align="center" style="background-color:#FFFFFF">0,4</td>
<td align="center" style="background-color:#FFFFFF">27,6</td>
<td align="center" style="background-color:#FFFFFF">123/565</td>
<td align="center" style="background-color:#FFFFFF">21,8</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">CSF</td>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="center" style="background-color:#FFFFFF">1/95</td>
<td align="center" style="background-color:#FFFFFF">1.1</td>
<td align="center" style="background-color:#FFFFFF">3/95</td>
<td align="center" style="background-color:#FFFFFF">3.2</td>
<td align="center" style="background-color:#FFFFFF">34,9</td>
<td align="center" style="background-color:#FFFFFF">16/95</td>
<td align="center" style="background-color:#FFFFFF">16,8</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">Placenta</td>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="center" style="background-color:#FFFFFF">3/58</td>
<td align="center" style="background-color:#FFFFFF">5.2</td>
<td align="center" style="background-color:#FFFFFF">4/58</td>
<td align="center" style="background-color:#FFFFFF">6.9</td>
<td align="center" style="background-color:#FFFFFF">21,7</td>
<td align="center" style="background-color:#FFFFFF">7/58</td>
<td align="center" style="background-color:#FFFFFF">12,1</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">Cord blood</td>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="center" style="background-color:#FFFFFF">2/56</td>
<td align="center" style="background-color:#FFFFFF">3.6</td>
<td align="center" style="background-color:#FFFFFF">2/56</td>
<td align="center" style="background-color:#FFFFFF">3.6</td>
<td align="center" style="background-color:#FFFFFF">23,8</td>
<td align="center" style="background-color:#FFFFFF">10/56</td>
<td align="center" style="background-color:#FFFFFF">17,9</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">AF</td>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="center" style="background-color:#FFFFFF">15/44</td>
<td align="center" style="background-color:#FFFFFF">34.1</td>
<td align="center" style="background-color:#FFFFFF">0/44</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">29,3</td>
<td align="center" style="background-color:#FFFFFF">5/44</td>
<td align="center" style="background-color:#FFFFFF">11,4</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">BALF<xref ref-type="table-fn" rid="t001fn003">**</xref></td>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="center" style="background-color:#FFFFFF">1/41</td>
<td align="center" style="background-color:#FFFFFF">2.4</td>
<td align="center" style="background-color:#FFFFFF">0/41</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">29.9</td>
<td align="center" style="background-color:#FFFFFF">5/41</td>
<td align="center" style="background-color:#FFFFFF">12.2</td>
<td align="center" style="background-color:#FFFFFF">51/787</td>
<td align="center" style="background-color:#FFFFFF">6,5</td>
<td align="center" style="background-color:#FFFFFF">12/787</td>
<td align="center" style="background-color:#FFFFFF">1.5</td>
<td align="center" style="background-color:#FFFFFF">24.7</td>
<td align="center" style="background-color:#FFFFFF">100/787</td>
<td align="center" style="background-color:#FFFFFF">12.7</td>
</tr>
<tr>
<td align="left" colspan="2" style="background-color:#FFFFFF">Aqueous humor</td>
<td align="center" style="background-color:#FFFFFF">2/28</td>
<td align="center" style="background-color:#FFFFFF">7.1</td>
<td align="center" style="background-color:#FFFFFF">0/28</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">33,6</td>
<td align="center" style="background-color:#FFFFFF">8/28</td>
<td align="center" style="background-color:#FFFFFF">28,6</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">Sputum</td>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">16/141</td>
<td align="center" style="background-color:#FFFFFF">11.4</td>
<td align="center" style="background-color:#FFFFFF">4/141</td>
<td align="center" style="background-color:#FFFFFF">2.8</td>
<td align="center" style="background-color:#FFFFFF">23,9</td>
<td align="center" style="background-color:#FFFFFF">23/141</td>
<td align="center" style="background-color:#FFFFFF">16,3</td>
</tr>
<tr>
<td align="left" colspan="2" style="background-color:#FFFFFF">Bronchoaspiration</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">1/35</td>
<td align="center" style="background-color:#FFFFFF">2.9</td>
<td align="center" style="background-color:#FFFFFF">1/35</td>
<td align="center" style="background-color:#FFFFFF">2.8</td>
<td align="center" style="background-color:#FFFFFF">22,1</td>
<td align="center" style="background-color:#FFFFFF">4/35</td>
<td align="center" style="background-color:#FFFFFF">11,4</td>
</tr>
<tr>
<td align="left" colspan="2" style="background-color:#FFFFFF">Miscellaneous<xref ref-type="table-fn" rid="t001fn003">**</xref></td>
<td align="center" style="background-color:#FFFFFF">1/29</td>
<td align="center" style="background-color:#FFFFFF">3.4</td>
<td align="center" style="background-color:#FFFFFF">3/29</td>
<td align="center" style="background-color:#FFFFFF">10,3</td>
<td align="center" style="background-color:#FFFFFF">32</td>
<td align="center" style="background-color:#FFFFFF">7/29</td>
<td align="center" style="background-color:#FFFFFF">24,1</td>
<td align="center" style="background-color:#FFFFFF">0/1</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">0/1</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">24.7</td>
<td align="center" style="background-color:#FFFFFF">0/1</td>
<td align="center" style="background-color:#FFFFFF">0</td>
</tr>
<tr>
<td align="left" />
<td align="left" style="background-color:#FFFFFF">Cerebral biopsy</td>
<td align="center" style="background-color:#FFFFFF">1/14</td>
<td align="center" style="background-color:#FFFFFF">7.1</td>
<td align="center" style="background-color:#FFFFFF">2/14</td>
<td align="center" style="background-color:#FFFFFF">14.3</td>
<td align="center" style="background-color:#FFFFFF">28,4</td>
<td align="center" style="background-color:#FFFFFF">1/14</td>
<td align="center" style="background-color:#FFFFFF">7.1</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="left" style="background-color:#FFFFFF">Lymph node</td>
<td align="center" style="background-color:#FFFFFF">0/6</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">0/6</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">28,4</td>
<td align="center" style="background-color:#FFFFFF">1/6</td>
<td align="center" style="background-color:#FFFFFF">16.7</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="left" style="background-color:#FFFFFF">Liver biopsy</td>
<td align="center" style="background-color:#FFFFFF">0/2</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">1/2</td>
<td align="center" style="background-color:#FFFFFF">50</td>
<td align="center" style="background-color:#FFFFFF">28,4</td>
<td align="center" style="background-color:#FFFFFF">1/2</td>
<td align="center" style="background-color:#FFFFFF">50</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="left" style="background-color:#FFFFFF">Ascites</td>
<td align="center" style="background-color:#FFFFFF">0/2</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">0/2</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">28,4</td>
<td align="center" style="background-color:#FFFFFF">1/2</td>
<td align="center" style="background-color:#FFFFFF">50</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="left" style="background-color:#FFFFFF">Pericardia fluid</td>
<td align="center" style="background-color:#FFFFFF">0/2</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">0/2</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">28,4</td>
<td align="center" style="background-color:#FFFFFF">1/2</td>
<td align="center" style="background-color:#FFFFFF">50</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="left" style="background-color:#FFFFFF">Pleural fluid</td>
<td align="center" style="background-color:#FFFFFF">0/1</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">0/1</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">28,4</td>
<td align="center" style="background-color:#FFFFFF">1/1</td>
<td align="center" style="background-color:#FFFFFF">100</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="left" style="background-color:#FFFFFF">Bone marrow</td>
<td align="center" style="background-color:#FFFFFF">0/1</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">0/1</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">28,4</td>
<td align="center" style="background-color:#FFFFFF">0/1</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="left" style="background-color:#FFFFFF">Retina</td>
<td align="center" style="background-color:#FFFFFF">0/1</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">0/1</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">28,4</td>
<td align="center" style="background-color:#FFFFFF">1/1</td>
<td align="center" style="background-color:#FFFFFF">100</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="left" style="background-color:#FFFFFF">Nasal aspiration</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">0/1</td>
<td align="center" style="background-color:#FFFFFF">0</td>
<td align="center" style="background-color:#FFFFFF">0/1</td>
<td align="center" style="background-color:#FFFFFF">-</td>
<td align="center" style="background-color:#FFFFFF">24,7</td>
<td align="center" style="background-color:#FFFFFF">0/1</td>
<td align="center" style="background-color:#FFFFFF">0</td>
</tr>
<tr>
<td align="left" style="background-color:#FFFFFF">Total</td>
<td align="left" style="background-color:#FFFFFF">&#160;</td>
<td align="left" style="background-color:#FFFFFF">37/2225</td>
<td align="center" style="background-color:#FFFFFF">1,7</td>
<td align="center" style="background-color:#FFFFFF">45/2225</td>
<td align="center" style="background-color:#FFFFFF">2</td>
<td align="center" style="background-color:#FFFFFF">&#160;</td>
<td align="center" style="background-color:#FFFFFF">285/2225</td>
<td align="center" style="background-color:#FFFFFF">12,8</td>
<td align="center" style="background-color:#FFFFFF">68/964</td>
<td align="center" style="background-color:#FFFFFF">7,1</td>
<td align="center" style="background-color:#FFFFFF">17/964</td>
<td align="center" style="background-color:#FFFFFF">1.8</td>
<td align="center" style="background-color:#FFFFFF">&#160;</td>
<td align="center" style="background-color:#FFFFFF">127/964</td>
<td align="center" style="background-color:#FFFFFF">13,2</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>CSF: cerebrospinal fluid; AF: amniotic fluid (including external quality assessment samples); BALF: bronchoalveolar lavage fluid. Samples were considered inhibited if Cp of amplification controls was &gt;38 for both amplification control wells for <italic>Toxoplasma</italic> PCR, and if &#916;Cp was &#8805;3 for <italic>Pneumocystis</italic> PCR</p></fn>
<fn id="t001fn002"><p>*threshold = mean Cp + 3</p></fn>
<fn id="t001fn003"><p>** for <italic>Toxoplasma</italic> and <italic>Pneumocystis</italic> PCR respectively, 37 BALF samples were analysed by both methods (for details, see <xref ref-type="sec" rid="sec002">Methods</xref>).</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec012">
<title>Inhibition rates in clinical samples as assessed from the pathogen-specific amplification control</title>
<p>Of the 3152 analysed samples, 62 (2.0%) showed evidence of PCR inhibition as assessed from the pathogen-specific amplification control: 45 samples for <italic>Toxoplasma</italic>-qPCR and 17 for <italic>Pneumocystis</italic>-qPCR (<xref ref-type="fig" rid="pone.0219276.g002">Fig 2</xref>). However, this percentage varied from 1.8&#8211;15% depending on the matrix (<xref ref-type="table" rid="pone.0219276.t001">Table 1</xref>). In 61/62 inhibited samples, tenfold dilution of the DNA extract released inhibition, confirming that the unexpected Cp values were due to PCR inhibitors. The remaining sample was a cord blood tested for the presence of <italic>Toxoplasma</italic> for which PCR remained inhibited despite the dilution, showing flat amplification curves for both the target- and the albumin-specific inhibition controls before and after tenfold dilution. No additional dilution was applied to this sample due to the risk of reduced sensitivity. Interestingly, blood samples, which are reported elsewhere [<xref ref-type="bibr" rid="pone.0219276.ref026">26</xref>] to be prone to PCR inhibition did not exhibit the highest inhibition rate in our study. Samples like sputum or placenta were also prone to PCR inhibition, probably because it is difficult to optimize a DNA extraction protocol for heterogeneous matrixes with highly different structures and properties from one sample to another. Using a similar pathogen-specific control method to detect PCR inhibitors in BALF samples, D&#246;skaya <italic>et al</italic>. found a 23.8% inhibition rate for <italic>Pneumocystis</italic> PCR [<xref ref-type="bibr" rid="pone.0219276.ref005">5</xref>] but a large study of Buckwalter <italic>et al</italic>. reported inhibition rates under 1% on 386,706 samples [<xref ref-type="bibr" rid="pone.0219276.ref004">4</xref>]. These discrepant results illustrate that PCR inhibition measurement is a problem of variable importance in routine practices, probably depending on the ability of extraction methods to remove inhibitors, on the susceptibility of PCR methods to inhibitors and on the performance of PCR inhibition detection.</p>
</sec>
<sec id="sec013">
<title>Performances of PCR inhibition detection using albumin-qPCR</title>
<p>409/3152 samples (12.9%) exhibited a Cp<sub>alb</sub> above the threshold, <italic>i</italic>.<italic>e</italic>. above the mean Cp for the matrix concerned + 3 (<xref ref-type="table" rid="pone.0219276.t001">Table 1</xref>). Thus, (i) the albumin-qPCR identified many more samples as containing inhibitors than the pathogen-specific controls, and this was so in both qPCR assays, <italic>i</italic>.<italic>e</italic>. 285 <italic>vs</italic>. 45 for the <italic>Toxoplasma</italic> assay, and 127 <italic>vs</italic>. 17 for the <italic>Pneumocystis</italic> assay. In addition, (ii) it is noteworthy that only 13 and 3 samples were detected as inhibited using both inhibitor-detection methods, for the <italic>Toxoplasma</italic> and <italic>Pneumocystis</italic> assays, respectively (<xref ref-type="fig" rid="pone.0219276.g002">Fig 2</xref>). We therefore conclude that (i) the human gene-based qPCR detected inhibitors much more often than the pathogen-specific qPCR and (ii) it most often did not detect them correctly. Considering this poor correlation between pathogen-specific controls and albumin qPCR to detect PCR inhibitors, we wished to determine Cp<sub>alb</sub> thresholds more adapted to our assays. To do so, we calculated the sensitivity, specificity of the albumin qPCR to detect PCR-inhibiting samples using the pathogen-specific control as reference and the Youden's index (Sensitivity + Specificity&#8211; 1) and we varied the Cp<sub>alb</sub> threshold (see <xref ref-type="sec" rid="sec002">Methods</xref> and <xref ref-type="fig" rid="pone.0219276.g003">Fig 3A</xref>). We could not determine a Cp<sub>alb</sub> threshold allowing to obtain 95% sensitivity and 95% specificity (<xref ref-type="fig" rid="pone.0219276.g003">Fig 3B</xref>), whether this strategy was used for all matrixes together or for each type of matrix (<xref ref-type="supplementary-material" rid="pone.0219276.s004">S3</xref> and <xref ref-type="supplementary-material" rid="pone.0219276.s005">S4</xref> Figs). We therefore concluded that no Cp<sub>alb</sub> cut-off values can be determined to efficiently detect pathogen-specific inhibitions for both pathogen-specific PCR assays. To check the influence of the cellularity of clinical samples on Cp<sub>alb</sub> values, we compared white blood cell counts to albumin qPCR results for blood samples. We analysed 1690/1874 blood samples; the remaining 184 samples were excluded from the analysis due to the absence of whole blood cell count on the same day as <italic>Toxoplasma</italic>-PCR. Cp<sub>alb</sub> values were correlated to leucocyte counts (p&lt;0.0001; Spearman&#8217;s rank correlation), but for a given white blood cell count a large range of Cp<sub>alb</sub> was observed (<xref ref-type="fig" rid="pone.0219276.g004">Fig 4</xref>). The lack of sensitivity and specificity of albumin PCR to detect target specific inhibitions may be explained by a differential susceptibility of each qPCR assay to inhibitors and by the variable quantity of human DNA in clinical samples. These results prevent using human gene-based PCR, <italic>e</italic>.<italic>g</italic>. albumin, betaglobin or human RNase P genes, as PCR inhibition detection method. We based our demonstration on two models, <italic>i</italic>.<italic>e</italic>. <italic>Toxoplasma</italic> and <italic>Pneumocystis</italic> but these results should be expanded to the detection of other pathogens in human samples.</p>
<fig id="pone.0219276.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0219276.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Youden&#8217;s index, sensitivity and specificity of albumin-PCR cut-off values.</title>
<p><bold>A and C</bold>. Black curves: Youden&#8217;s index = sensitivity + specificity&#8211; 1; <bold>B and D</bold>. Red curves: sensitivity; blue curves: specificity. For <italic>Toxoplasma</italic> qPCR <bold>(A)</bold>, the maximal Youden&#8217;s index was very low. The maximum value was 0.19 and was reached for a Cp<sub>alb</sub> cut-off value of 36. At this albumin qPCR cut-off value sensitivity is 20% (p&lt; 0.0001; Binomial test for 95% theoretical sensitivity) and specificity 98.8% (p = 1, Binomial test for 95% theoretical specificity). <bold>(B)</bold> Graphical analysis of sensitivity and specificity curves in function of cut-off values. Both curves intersect at a Cp<sub>alb</sub> value of 22. At this Cp<sub>alb</sub> cut-off value sensitivity is 33.3% and specificity 66.6% (p&lt;0.0001 and p&lt;0.0001; Binomial tests for 95% theoretical sensitivity and specificity). For <italic>Pneumocystis</italic> qPCR <bold>(C)</bold>, the maximal Youden&#8217;s index was too low to allow determining any Cp<sub>alb</sub> cut-off value. <bold>(D)</bold> Graphical profiles of sensitivity and curves in function of cut-off values. Both curves intersect at a Cp<sub>alb</sub> value of 22. At this Cp<sub>alb</sub> cut-off value sensitivity is 47.1% and specificity 62% (p&lt;0.0001 and p&lt;0.0001; Binomial tests for 95% theoretical sensitivity and specificity).</p>
</caption>
<graphic mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0219276.g003" ns0:type="simple" />
</fig>
<fig id="pone.0219276.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0219276.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Correlation between leucocyte counts and Cp<sub>alb</sub> values in 1690 blood samples.</title>
<p>Semi-log scale graph where leucocyte count (x-axis) was plotted against Cp<sub>alb</sub> (orange and green dots corresponding to amplification control inhibited and not inhibited samples respectively). Linear model was used to determine trend line (Blue) with 95% confidence interval (Grey).</p>
</caption>
<graphic mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0219276.g004" ns0:type="simple" />
</fig>
<p>Another widely used method to search for inhibitors is the use of commercial &#8220;universal&#8221; controls. These commercial controls are made of exogenous DNA and are added either in the sample before extraction or with the DNA extract in the PCR mix. Differential susceptibility to inhibitors and efficiency discrepancies between PCR assays should also prove problematic in this approach. Indeed, the size and GC rate of the amplicons of the foreign DNA used will have an impact on the detection of the inhibition [<xref ref-type="bibr" rid="pone.0219276.ref013">13</xref>]. So, implementation of one of these controls should be avoided until their performances have been assessed in routine practice.</p>
<p>In conclusion, pathogen-specific amplification controls appear to be a method of choice for screening the presence of inhibitors in a PCR assay for infectious diseases as compared to the use of a human gene-based qPCR.</p>
</sec>
</sec>
<sec id="sec014">
<title>Supporting information</title>
<supplementary-material id="pone.0219276.s001" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" ns0:href="info:doi/10.1371/journal.pone.0219276.s001" ns0:type="simple">
<label>S1 Table</label>
<caption>
<title>Spreadsheet of raw data.</title>
<p>(XLSX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0219276.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" ns0:href="info:doi/10.1371/journal.pone.0219276.s002" ns0:type="simple">
<label>S1 Fig</label>
<caption>
<title>Flow chart of data cleaning and tidying of <italic>Toxoplasma</italic> PCR results.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0219276.s003" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" ns0:href="info:doi/10.1371/journal.pone.0219276.s003" ns0:type="simple">
<label>S2 Fig</label>
<caption>
<title>Flow chart of data cleaning and tidying of <italic>Pneumocystis</italic> PCR results.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0219276.s004" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" ns0:href="info:doi/10.1371/journal.pone.0219276.s004" ns0:type="simple">
<label>S3 Fig</label>
<caption>
<title>Youden&#8217;s index, sensitivity and specificity of albumin PCR cut-off values for the most frequent matrixes analysed in <italic>Toxoplasma</italic> PCR.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0219276.s005" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" ns0:href="info:doi/10.1371/journal.pone.0219276.s005" ns0:type="simple">
<label>S4 Fig</label>
<caption>
<title>Youden&#8217;s index, sensitivity and specificity of albumin PCR cut-off values for the most frequent matrixes analysed in <italic>Pneumocystis</italic> PCR.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We are grateful to S. Douzou, B. Sanichanh and G. Serres for their technical help.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0219276.ref001"><label>1</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Hedman</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Radstrom</surname> <given-names>P</given-names></name>. <article-title>Overcoming inhibition in real-time diagnostic PCR</article-title>. <source>Methods Mol Biol</source>. <year>2013</year>;<volume>943</volume>:<fpage>17</fpage>&#8211;<lpage>48</lpage>. Epub 2012/10/30. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1007/978-1-60327-353-4_2" ns0:type="simple">10.1007/978-1-60327-353-4_2</ext-link></comment> <object-id pub-id-type="pmid">23104280</object-id>.</mixed-citation></ref>
<ref id="pone.0219276.ref002"><label>2</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Wallace</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>MacKay</surname> <given-names>WG</given-names></name>. <article-title>Quality in the molecular microbiology laboratory</article-title>. <source>Methods Mol Biol</source>. <year>2013</year>;<volume>943</volume>:<fpage>49</fpage>&#8211;<lpage>79</lpage>. Epub 2012/10/30. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1007/978-1-60327-353-4_3" ns0:type="simple">10.1007/978-1-60327-353-4_3</ext-link></comment> <object-id pub-id-type="pmid">23104281</object-id>.</mixed-citation></ref>
<ref id="pone.0219276.ref003"><label>3</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Schrader</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Schielke</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ellerbroek</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Johne</surname> <given-names>R</given-names></name>. <article-title>PCR inhibitors&#8212;occurrence, properties and removal</article-title>. <source>J Appl Microbiol</source>. <year>2012</year>;<volume>113</volume>(<issue>5</issue>):<fpage>1014</fpage>&#8211;<lpage>26</lpage>. Epub 2012/07/04. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1111/j.1365-2672.2012.05384.x" ns0:type="simple">10.1111/j.1365-2672.2012.05384.x</ext-link></comment> <object-id pub-id-type="pmid">22747964</object-id>.</mixed-citation></ref>
<ref id="pone.0219276.ref004"><label>4</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Buckwalter</surname> <given-names>SP</given-names></name>, <name name-style="western"><surname>Sloan</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Cunningham</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Espy</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Uhl</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Jones</surname> <given-names>MF</given-names></name>, <etal>et al</etal>. <article-title>Inhibition controls for qualitative real-time PCR assays: are they necessary for all specimen matrices?</article-title> <source>J Clin Microbiol</source>. <year>2014</year>;<volume>52</volume>(<issue>6</issue>):<fpage>2139</fpage>&#8211;<lpage>43</lpage>. Epub 2014/04/18. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/JCM.03389-13" ns0:type="simple">10.1128/JCM.03389-13</ext-link></comment> <object-id pub-id-type="pmid">24740078</object-id>; PubMed Central PMCID: PMC4042775.</mixed-citation></ref>
<ref id="pone.0219276.ref005"><label>5</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Doskaya</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Caner</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Degirmenci</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wengenack</surname> <given-names>NL</given-names></name>, <name name-style="western"><surname>Yolasigmaz</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Turgay</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Degree and frequency of inhibition in a routine real-time PCR detecting Pneumocystis jirovecii for the diagnosis of Pneumocystis pneumonia in Turkey</article-title>. <source>J Med Microbiol</source>. <year>2011</year>;<volume>60</volume>(<issue>Pt 7</issue>):<fpage>937</fpage>&#8211;<lpage>44</lpage>. Epub 2011/04/05. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1099/jmm.0.030775-0" ns0:type="simple">10.1099/jmm.0.030775-0</ext-link></comment> <object-id pub-id-type="pmid">21459903</object-id>.</mixed-citation></ref>
<ref id="pone.0219276.ref006"><label>6</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Bustin</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Beaulieu</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Huggett</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jaggi</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kibenge</surname> <given-names>FS</given-names></name>, <name name-style="western"><surname>Olsvik</surname> <given-names>PA</given-names></name>, <etal>et al</etal>. <article-title>MIQE precis: Practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments.</article-title> <source>BMC Mol Biol</source>. 11. England2010. p. <fpage>74</fpage>.</mixed-citation></ref>
<ref id="pone.0219276.ref007"><label>7</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Sterkers</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Varlet-Marie</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Marty</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Bastien</surname> <given-names>P</given-names></name>. <article-title>Diversity and evolution of methods and practices for the molecular diagnosis of congenital toxoplasmosis in France: a 4-year survey</article-title>. <source>Clin Microbiol Infect</source>. <year>2010</year>;<volume>16</volume>(<issue>10</issue>):<fpage>1594</fpage>&#8211;<lpage>602</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1111/j.1469-0691.2009.03101.x" ns0:type="simple">10.1111/j.1469-0691.2009.03101.x</ext-link></comment> <object-id pub-id-type="pmid">19886905</object-id>.</mixed-citation></ref>
<ref id="pone.0219276.ref008"><label>8</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Rosenstraus</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>SY</given-names></name>, <name name-style="western"><surname>DeBonville</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Spadoro</surname> <given-names>JP</given-names></name>. <article-title>An internal control for routine diagnostic PCR: design, properties, and effect on clinical performance</article-title>. <source>J Clin Microbiol</source>. <year>1998</year>;<volume>36</volume>(<issue>1</issue>):<fpage>191</fpage>&#8211;<lpage>7</lpage>. Epub 1998/02/12. <object-id pub-id-type="pmid">9431945</object-id>; PubMed Central PMCID: PMC124832.</mixed-citation></ref>
<ref id="pone.0219276.ref009"><label>9</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Maaroufi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>de Bruyne</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Duchateau</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Scheen</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Crokaert</surname> <given-names>F</given-names></name>. <article-title>Development of a multiple internal control for clinical diagnostic real-time amplification assays</article-title>. <source>FEMS Immunol Med Microbiol</source>. <year>2006</year>;<volume>48</volume>(<issue>2</issue>):<fpage>183</fpage>&#8211;<lpage>91</lpage>. Epub 2006/10/27. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1111/j.1574-695X.2006.00125.x" ns0:type="simple">10.1111/j.1574-695X.2006.00125.x</ext-link></comment> <object-id pub-id-type="pmid">17064275</object-id>.</mixed-citation></ref>
<ref id="pone.0219276.ref010"><label>10</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Brenier-Pinchart</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Morand-Bui</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Fricker-Hidalgo</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Equy</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Marlu</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Pelloux</surname> <given-names>H</given-names></name>. <article-title>Adapting a conventional PCR assay for Toxoplasma gondii detection to real-time quantitative PCR including a competitive internal control</article-title>. <source>Parasite</source>. <year>2007</year>;<volume>14</volume>(<issue>2</issue>):<fpage>149</fpage>&#8211;<lpage>54</lpage>. Epub 2007/07/25. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1051/parasite/2007142149" ns0:type="simple">10.1051/parasite/2007142149</ext-link></comment> <object-id pub-id-type="pmid">17645187</object-id>.</mixed-citation></ref>
<ref id="pone.0219276.ref011"><label>11</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Daval</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Poirier</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Armenaud</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Cambon</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Livrelli</surname> <given-names>V</given-names></name>. [<article-title>Development of a real-time PCR assay for quantitative diagnosis of Toxoplasma gondii after allogeneic bone marrow transplantation</article-title>]. <source>Pathol Biol (Paris).</source> <year>2010</year>;<volume>58</volume>(<issue>1</issue>):<fpage>104</fpage>&#8211;<lpage>9</lpage>. Epub 2009/11/07. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.patbio.2009.07.013" ns0:type="simple">10.1016/j.patbio.2009.07.013</ext-link></comment> <object-id pub-id-type="pmid">19892493</object-id></mixed-citation></ref>
<ref id="pone.0219276.ref012"><label>12</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Huggett</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Novak</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Garson</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Green</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Morris-Jones</surname> <given-names>SD</given-names></name>, <name name-style="western"><surname>Miller</surname> <given-names>RF</given-names></name>, <etal>et al</etal>. <article-title>Differential susceptibility of PCR reactions to inhibitors: an important and unrecognised phenomenon.</article-title> <source>BMC Res Notes</source>. <year>2008</year>;<volume>1</volume>:<fpage>70</fpage>. Epub 2008/08/30. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1186/1756-0500-1-70" ns0:type="simple">10.1186/1756-0500-1-70</ext-link></comment> <object-id pub-id-type="pmid">18755023</object-id>; PubMed Central PMCID: PMC2564953.</mixed-citation></ref>
<ref id="pone.0219276.ref013"><label>13</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Pionzio</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>McCord</surname> <given-names>BR</given-names></name>. <article-title>The effect of internal control sequence and length on the response to PCR inhibition in real-time PCR quantitation.</article-title> <source>Forensic Sci Int Genet</source>. <year>2014</year>;<volume>9</volume>:<fpage>55</fpage>&#8211;<lpage>60</lpage>. Epub 2014/02/18. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.fsigen.2013.10.010" ns0:type="simple">10.1016/j.fsigen.2013.10.010</ext-link></comment> <object-id pub-id-type="pmid">24528580</object-id>.</mixed-citation></ref>
<ref id="pone.0219276.ref014"><label>14</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Chabbert</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Lachaud</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Crobu</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Bastien</surname> <given-names>P</given-names></name>. <article-title>Comparison of two widely used PCR primer systems for detection of toxoplasma in amniotic fluid, blood, and tissues</article-title>. <source>J Clin Microbiol</source>. <year>2004</year>;<volume>42</volume>(<issue>4</issue>):<fpage>1719</fpage>&#8211;<lpage>22</lpage>. 173. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/JCM.42.4.1719-1722.2004" ns0:type="simple">10.1128/JCM.42.4.1719-1722.2004</ext-link></comment> <object-id pub-id-type="pmid">15071031</object-id></mixed-citation></ref>
<ref id="pone.0219276.ref015"><label>15</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Hohlfeld</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Daffos</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Costa</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Thulliez</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Forestier</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Vidaud</surname> <given-names>M</given-names></name>. <article-title>Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid</article-title>. <source>N Engl J Med</source>. <year>1994</year>;<volume>331</volume>(<issue>11</issue>):<fpage>695</fpage>&#8211;<lpage>9</lpage>. Epub 1994/09/15. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1056/NEJM199409153311102" ns0:type="simple">10.1056/NEJM199409153311102</ext-link></comment> <object-id pub-id-type="pmid">8058075</object-id>.</mixed-citation></ref>
<ref id="pone.0219276.ref016"><label>16</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Sterkers</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Pratlong</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Albaba</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Loubersac</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Picot</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Pretet</surname> <given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Novel interpretation of molecular diagnosis of congenital toxoplasmosis according to gestational age at the time of maternal infection</article-title>. <source>J Clin Microbiol</source>. <year>2012</year>;<volume>50</volume>(<issue>12</issue>):<fpage>3944</fpage>&#8211;<lpage>51</lpage>. Epub 2012/10/05. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/JCM.00918-12" ns0:type="simple">10.1128/JCM.00918-12</ext-link></comment> <object-id pub-id-type="pmid">23035201</object-id>; PubMed Central PMCID: PMC3502944.</mixed-citation></ref>
<ref id="pone.0219276.ref017"><label>17</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Delhaes</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Filisetti</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Brenier-Pinchart</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Pelloux</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Yera</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Dalle</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Freezing and storage at -20 degrees C provides adequate preservation of Toxoplasma gondii DNA for retrospective molecular analysis</article-title>. <source>Diagn Microbiol Infect Dis</source>. <year>2014</year>;<volume>80</volume>(<issue>3</issue>):<fpage>197</fpage>&#8211;<lpage>9</lpage>. Epub 2014/09/23. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.diagmicrobio.2014.08.007" ns0:type="simple">10.1016/j.diagmicrobio.2014.08.007</ext-link></comment> <object-id pub-id-type="pmid">25241642</object-id>.</mixed-citation></ref>
<ref id="pone.0219276.ref018"><label>18</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Reischl</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Bretagne</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kruger</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Ernault</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Costa</surname> <given-names>JM</given-names></name>. <article-title>Comparison of two DNA targets for the diagnosis of Toxoplasmosis by real-time PCR using fluorescence resonance energy transfer hybridization probes</article-title>. <source>BMC Infect Dis</source>. <year>2003</year>;<volume>3</volume>:<fpage>7</fpage>. Epub 2003/05/06. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1186/1471-2334-3-7" ns0:type="simple">10.1186/1471-2334-3-7</ext-link></comment> <object-id pub-id-type="pmid">12729464</object-id>; PubMed Central PMCID: PMC156600.</mixed-citation></ref>
<ref id="pone.0219276.ref019"><label>19</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Fillaux</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Berry</surname> <given-names>A</given-names></name>. <article-title>Real-time PCR assay for the diagnosis of Pneumocystis jirovecii pneumonia</article-title>. <source>Methods Mol Biol</source>. <year>2013</year>;<volume>943</volume>:<fpage>159</fpage>&#8211;<lpage>70</lpage>. Epub 2012/10/30. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1007/978-1-60327-353-4_11" ns0:type="simple">10.1007/978-1-60327-353-4_11</ext-link></comment> <object-id pub-id-type="pmid">23104289</object-id>.</mixed-citation></ref>
<ref id="pone.0219276.ref020"><label>20</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Westgard</surname> <given-names>JO</given-names></name>, <name name-style="western"><surname>Barry</surname> <given-names>PL</given-names></name>, <name name-style="western"><surname>Hunt</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Groth</surname> <given-names>T</given-names></name>. <article-title>A multi-rule Shewhart chart for quality control in clinical chemistry</article-title>. <source>Clin Chem</source>. <year>1981</year>;<volume>27</volume>(<issue>3</issue>):<fpage>493</fpage>&#8211;<lpage>501</lpage>. Epub 1981/03/01. <object-id pub-id-type="pmid">7471403</object-id>.</mixed-citation></ref>
<ref id="pone.0219276.ref021"><label>21</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Mary</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Faraut</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Lascombe</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Dumon</surname> <given-names>H</given-names></name>. <article-title>Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity</article-title>. <source>J Clin Microbiol</source>. <year>2004</year>;<volume>42</volume>(<issue>11</issue>):<fpage>5249</fpage>&#8211;<lpage>55</lpage>. Epub 2004/11/06. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/JCM.42.11.5249-5255.2004" ns0:type="simple">10.1128/JCM.42.11.5249-5255.2004</ext-link></comment> <object-id pub-id-type="pmid">15528722</object-id>; PubMed Central PMCID: PMC525214.</mixed-citation></ref>
<ref id="pone.0219276.ref022"><label>22</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Varlet-Marie</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Sterkers</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Brenier-Pinchart</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Cassaing</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Dalle</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Delhaes</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Characterization and multicentric validation of a common standard for Toxoplasma gondii detection using nucleic acid amplification assays</article-title>. <source>J Clin Microbiol</source>. <year>2014</year>;<volume>52</volume>(<issue>11</issue>):<fpage>3952</fpage>&#8211;<lpage>9</lpage>. Epub 2014/09/05. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/JCM.01906-14" ns0:type="simple">10.1128/JCM.01906-14</ext-link></comment> <object-id pub-id-type="pmid">25187637</object-id>; PubMed Central PMCID: PMC4313224.</mixed-citation></ref>
<ref id="pone.0219276.ref023"><label>23</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Kralik</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Ricchi</surname> <given-names>M</given-names></name>. <article-title>A Basic Guide to Real Time PCR in Microbial Diagnostics: Definitions, Parameters, and Everything</article-title>. <source>Front Microbiol</source>. <year>2017</year>;<volume>8</volume>:<fpage>108</fpage>. Epub 2017/02/18. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.3389/fmicb.2017.00108" ns0:type="simple">10.3389/fmicb.2017.00108</ext-link></comment> <object-id pub-id-type="pmid">28210243</object-id>; PubMed Central PMCID: PMC5288344.</mixed-citation></ref>
<ref id="pone.0219276.ref024"><label>24</label><mixed-citation publication-type="book" ns0:type="simple"><collab>RCore-Team</collab>. <chapter-title>R: a language and environment for statistical computing</chapter-title>: <publisher-name>R Foundation for Statistical Computing</publisher-name>, <publisher-loc>Vienna, Austria</publisher-loc>.; <year>2017</year>. Available from: <ext-link ext-link-type="uri" ns0:href="https://www.R-project.org" ns0:type="simple">https://www.R-project.org</ext-link>.</mixed-citation></ref>
<ref id="pone.0219276.ref025"><label>25</label><mixed-citation publication-type="book" ns0:type="simple"><collab>RStudio-Team</collab>. <chapter-title>R Studio: Integrated Development for R</chapter-title>.: <publisher-name>RStudio, Inc</publisher-name>., <publisher-loc>Boston, MA</publisher-loc>; <year>2015</year>. Available from: <ext-link ext-link-type="uri" ns0:href="http://www.rstudio.com" ns0:type="simple">http://www.rstudio.com</ext-link>.</mixed-citation></ref>
<ref id="pone.0219276.ref026"><label>26</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Al-Soud</surname> <given-names>WA</given-names></name>, <name name-style="western"><surname>Radstrom</surname> <given-names>P</given-names></name>. <article-title>Purification and characterization of PCR-inhibitory components in blood cells</article-title>. <source>J Clin Microbiol</source>. <year>2001</year>;<volume>39</volume>(<issue>2</issue>):<fpage>485</fpage>&#8211;<lpage>93</lpage>. Epub 2001/02/07. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/JCM.39.2.485-493.2001" ns0:type="simple">10.1128/JCM.39.2.485-493.2001</ext-link></comment> <object-id pub-id-type="pmid">11158094</object-id>; PubMed Central PMCID: PMC87763.</mixed-citation></ref>
</ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pone.0219276.r001" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0219276.r001</article-id>
<title-group>
<article-title>Decision Letter 0</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Marangoni</surname>
<given-names>Antonella</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Antonella Marangoni</copyright-holder>
<license ns0:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0219276" document-id-type="doi" document-type="article" id="rel-obj001" link-type="peer-reviewed-article" />
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>0</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">26 Jul 2019</named-content>
</p>
<p>PONE-D-19-16663</p>
<p>Original research. Inhibition of Polymerase Chain Reaction: Pathogen-Specific Controls are better than Human Gene Amplification</p>
<p>PLOS ONE</p>
<p>Dear Dr Sterkers,</p>
<p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#8217;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>==============================</p>
<p>The paper is definetely worthy, but I feel that the statistics evaluation could be improved.</p>
<p>Follow the suggestions given by the referee and check the quality of your images.</p>
<p>==============================</p>
<p>We would appreciate receiving your revised manuscript by August, 14th. When you are ready to submit your revision, log on to <ext-link ext-link-type="uri" ns0:href="https://www.editorialmanager.com/pone/" ns0:type="simple">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.</p>
<p>To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" ns0:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ns0:type="simple">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link></p>
<p>Please include the following items when submitting your revised manuscript:</p>
<p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.</p></list-item></list></p>
<p>Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Antonella Marangoni, Ph.D.</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p>Journal requirements:</p>
<p>When submitting your revision, we need you to address these additional requirements.</p>
<p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
<p><ext-link ext-link-type="uri" ns0:href="http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ns0:type="simple">http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and <ext-link ext-link-type="uri" ns0:href="http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ns0:type="simple">http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link></p>
<p>2. Thank you for stating the following in the Financial Disclosure section:</p>
<p>""RSI Assurance Maladie Professions Lib&#233;rales - Provinces. C.A.M.P.L.P." has paid the LightCycler 480 (Roche&#174;) real-time PCR equipment in 2009</p>
<p>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."</p>
<p>We note that you received funding from a commercial source: RSI Assurance Maladie Professions Lib&#233;rales - Provinces. C.A.M.P.L.P.</p>
<p>Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc.</p>
<p>Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.&#8221; (as detailed online in our guide for authors <ext-link ext-link-type="uri" ns0:href="http://journals.plos.org/plosone/s/competing-interests" ns0:type="simple">http://journals.plos.org/plosone/s/competing-interests</ext-link>). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.</p>
<p>Please respond by return email with your amended Competing Interests Statement and we will change the online submission form on your behalf.</p>
<p>Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <ext-link ext-link-type="uri" ns0:href="http://journals.plos.org/plosone/s/competing-interests" ns0:type="simple">http://journals.plos.org/plosone/s/competing-interests</ext-link></p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p><bold>Comments to the Author</bold></p>
<p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>2. Has the statistical analysis been performed appropriately and rigorously? </p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
<p>The <ext-link ext-link-type="uri" ns0:href="http://www.plosone.org/static/policies.action#sharing" ns0:type="simple">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p>
<p>Reviewer #1: No</p>
<p>**********</p>
<p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
<p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>5. Review Comments to the Author</p>
<p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
<p>Reviewer #1: Authors present their work on inhibition of PCR. I found this work useful. Following are my few suggestions in general and few minor edits for the manuscript, that authors may consider.</p>
<p>Overall, it&#8217;ll be a good to provide a brief discussion of the work in the context of it&#8217;s utility to other type of pathogens as well. In addition, it&#8217;ll be helpful for others if authors could provide the analysis pipeline on GitHub or something similar. Since they used R, therefore it should be easy. Authors may also improve the quality of figures as I found them bit blurred.</p>
<p>Minor comments</p>
<p>Line 140: I think it should be pathogen- specific amplification.</p>
<p>Line 148-150: Is the p-value significant computed after correction or before?</p>
<p>Line 194: should be pathogen-specific control. Also, please check space issues elsewhere in the article.</p>
<p>**********</p>
<p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" ns0:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ns0:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" ns0:href="https://www.plos.org/privacy-policy" ns0:type="simple">Privacy Policy</ext-link>.</p>
<p>Reviewer #1: No</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]</p>
<p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" ns0:href="https://pacev2.apexcovantage.com/" ns0:type="simple">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <email ns0:type="simple">figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pone.0219276.r002">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0219276.r002</article-id>
<title-group>
<article-title>Author response to Decision Letter 0</article-title>
</title-group>
<related-object document-id="10.1371/journal.pone.0219276" document-id-type="doi" document-type="peer-reviewed-article" id="rel-obj002" link-type="rebutted-decision-letter" object-id="10.1371/journal.pone.0219276.r001" object-id-type="doi" object-type="decision-letter" />
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="author-response-date">16 Aug 2019</named-content>
</p>
<p>We were able to addresses all the points raised during the review process, see the uploaded response to reviewer file</p>
<supplementary-material id="pone.0219276.s006" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" ns0:href="info:doi/10.1371/journal.pone.0219276.s006" ns0:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Roux_Inhibitors_ResponseToReviewers_PLoSOnev190816.docx</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pone.0219276.r003" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0219276.r003</article-id>
<title-group>
<article-title>Decision Letter 1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Marangoni</surname>
<given-names>Antonella</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Antonella Marangoni</copyright-holder>
<license ns0:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0219276" document-id-type="doi" document-type="article" id="rel-obj003" link-type="peer-reviewed-article" />
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">26 Aug 2019</named-content>
</p>
<p>[EXSCINDED]</p>
<p>Original research. Inhibition of Polymerase Chain Reaction: Pathogen-Specific Controls are better than Human Gene Amplification</p>
<p>PONE-D-19-16663R1</p>
<p>Dear Dr. Sterkers,</p>
<p>We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.</p>
<p>Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.</p>
<p>Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <ext-link ext-link-type="uri" ns0:href="https://www.editorialmanager.com/pone/" ns0:type="simple">https://www.editorialmanager.com/pone/</ext-link>, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <email ns0:type="simple">authorbilling@plos.org</email>.</p>
<p>If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email ns0:type="simple">onepress@plos.org</email>.</p>
<p>With kind regards,</p>
<p>Antonella Marangoni, Ph.D.</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p>Additional Editor Comments (optional):</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p><bold>Comments to the Author</bold></p>
<p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#8220;Comments to the Author&#8221; section, enter your conflict of interest statement in the &#8220;Confidential to Editor&#8221; section, and submit your "Accept" recommendation.</p>
<p>Reviewer #1: All comments have been addressed</p>
<p>**********</p>
<p>2. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>3. Has the statistical analysis been performed appropriately and rigorously? </p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p>
<p>The <ext-link ext-link-type="uri" ns0:href="http://www.plosone.org/static/policies.action#sharing" ns0:type="simple">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
<p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>6. Review Comments to the Author</p>
<p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
<p>Reviewer #1: (No Response)</p>
<p>**********</p>
<p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" ns0:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ns0:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" ns0:href="https://www.plos.org/privacy-policy" ns0:type="simple">Privacy Policy</ext-link>.</p>
<p>Reviewer #1: No</p>
</body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0219276.r004" specific-use="acceptance-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0219276.r004</article-id>
<title-group>
<article-title>Acceptance letter</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Marangoni</surname>
<given-names>Antonella</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Antonella Marangoni</copyright-holder>
<license ns0:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0219276" document-id-type="doi" document-type="article" id="rel-obj004" link-type="peer-reviewed-article" />
</front-stub>
<body>
<p>
<named-content content-type="letter-date">20 Sep 2019</named-content>
</p>
<p>PONE-D-19-16663R1 </p>
<p>Inhibition of Polymerase Chain Reaction: Pathogen-Specific Controls are better than Human Gene Amplification. </p>
<p>Dear Dr. Sterkers:</p>
<p>I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
<p>If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email ns0:type="simple">onepress@plos.org</email>.</p>
<p>For any other questions or concerns, please email <email ns0:type="simple">plosone@plos.org</email>. </p>
<p>Thank you for submitting your work to PLOS ONE.</p>
<p>With kind regards,</p>
<p>PLOS ONE Editorial Office Staff</p>
<p>on behalf of</p>
<p>PhD Antonella Marangoni  </p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
</body>
</sub-article>
</article>